A Study of Taspoglutide in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This crossover study will assess the effect of 2 doses of Taspoglutide on first- and
second-phase insulin secretion in patients with type 2 diabetes. Patients will receive a
continuous subcutaneous infusion of a)the Immediate Release Formulation (IRF)of Taspoglutide
300 micrograms/day for 2 days followed by Taspoglutide 800 micrograms/day for 2 days or
b)saline placebo for 2+2 days. After a washout period of 10-15 days, patients will be
crossed-over for further treatment;those receiving Taspoglutide in period 1 will receive
placebo in period 2, and vice versa. On days 2 and 4 of each period, insulin secretion
patterns will be assessed. The anticipated time on study treatment is <3 months, and the
target sample size is <100 individuals.